Cargando…
C(60) Fullerene as Synergistic Agent in Tumor-Inhibitory Doxorubicin Treatment
BACKGROUND: Doxorubicin (Dox) is one of the most potent anticancer drugs, but its successful use is hampered by high toxicity caused mainly by generation of reactive oxygen species. One approach to protect against Dox-dependent chemical insult is combined use of the cytostatic drug with antioxidants...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269825/ https://www.ncbi.nlm.nih.gov/pubmed/25504158 http://dx.doi.org/10.1007/s40268-014-0074-4 |